Summary & Overview
CPT 81330: SMPD1 Gene Variant Detection
CPT code 81330 represents a molecular diagnostic laboratory procedure to detect common genetic changes in the SMPD1 gene, which encodes sphingomyelin phosphodiesterase 1. This genetic test is clinically significant for diagnosing and characterizing lysosomal storage disorders related to sphingomyelin metabolism and can affect diagnostic pathways, genetic counseling, and care planning across the country. Nationally, molecular and genetic testing codes like CPT 81330 are increasingly important as precision medicine expands and payers refine coverage policies for targeted diagnostics. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of the clinical context and the laboratory service represented by CPT code 81330, summaries of common payer approaches and coverage considerations, and what to expect in terms of typical sites of service and service type. The publication also highlights benchmarking elements, recent policy trends that affect molecular diagnostic billing, and practical information for billing and claims submissions. Data not available in the input is clearly noted where relevant.
Billing Code Overview
CPT code 81330 describes a laboratory technical procedure that detects common sequence changes in the SMPD1 gene, which encodes sphingomyelin phosphodiesterase 1 (acid lysosomal). This test identifies genetic variants associated with disorders of sphingomyelin metabolism.
-
Service type: Molecular diagnostic laboratory test (genetic sequencing/variant detection)
-
Typical site of service: Clinical diagnostic laboratory or molecular pathology laboratory (specimen collected in an outpatient or inpatient setting and processed in a lab)
Clinical & Coding Specifications
Clinical Context
A patient referred to a molecular diagnostics laboratory for evaluation of suspected Niemann-Pick disease type A or B undergoes genetic testing targeted to the acid sphingomyelinase gene (SMPD1). Typical patients are infants or children presenting with progressive hepatosplenomegaly, failure to thrive, developmental delay, hypotonia, recurrent respiratory infections, or neurodegeneration. Adults with unexplained splenomegaly and cytopenias may also be tested when a late-onset variant is suspected.
In a common clinical workflow, the ordering clinician (pediatrician, geneticist, or hematologist) documents clinical findings and orders CPT 81330 for targeted molecular analysis of common SMPD1 variants. The specimen (blood or buccal) is collected in the clinic or phlebotomy suite and sent to a certified molecular lab. The lab analyst performs DNA extraction, variant-targeted testing (e.g., PCR-based assay or targeted sequencing for common pathogenic variants), and generates a technical report. A laboratory director reviews results and issues the finalized report to the ordering provider, who interprets findings in the clinical context and counsels the patient/family regarding diagnosis, carrier status, and potential genetic counseling referrals.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|